In the current trading session, ARS Pharmaceuticals Inc’s (SPRY) stock is trading at the price of $10.6, a fall of -0.33% over last night’s close. So, the stock is trading at a price that is -43.94% less than its 52-week high of $18.90 and 59.08% better than its 52-week low of $6.66.
It is also essential to consider SPRY stock ratios like the price-to-sales ratio, which is 7.34 for the last year.SPRY’s price to book ratio for the most recent quarter was 7.09, resulting in an 3.63 price to cash per share for the period.
How does ARS Pharmaceuticals Inc (SPRY) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
ARS Pharmaceuticals Inc (SPRY): Earnings History
If we examine ARS Pharmaceuticals Inc’s recent earnings history, in the last quarter ended on 9/30/2025, it posted adjusted earnings per share of -$0.52, beating the consensus of -$0.49. In other words, it beat the consensus by -$0.03, resulting in a -6.12% surprise. In the 3 months period before the previous quarter which was closed on 9/30/2025, the stock recorded adjusted earnings per share of -$0.52 in contrast with the Outlook of -$0.49. That was a difference of -$0.03 and a surprise of -6.12%.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Ownership Details
I will give a breakdown of the key shareholders in ARS Pharmaceuticals Inc (SPRY). Recent figures show that the company’s insiders hold 16.83% of shares. A total of 264 institutional investors hold shares in the company, making 87.11% of its stock and 104.73% of its float.
Sep 30, 2025, it was reported that the Company’s largest institutional holder is RA Capital Management, L.P. holding total of 10.86 shares that make 10.99% of the company’s total number of shares and are currently priced at 115.02 million.
The securities firm Orbimed Advisors LLC. holds 8.29 shares of SPRY, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 8.39%, and the holding percentage of shares is valued at 87.78 million.
